Adjuvant radiotherapy and chemotherapy for resected pancreatic adenocarcinoma: Review of current evidence

Michelle A. Neben-Wittich, Michael C. Stauder, Fernando Quevedo, Michele M. Corsini, Matthew J. Iott, Robert C. Miller

Research output: Contribution to journalArticle

Abstract

Pancreatic adenocarcinoma is an aggressive cancer with an overall 5-year survival of 5% or less. In patients who have resectable tumors, resection can lead to an improvement in overall survival, but local and distant recurrence rates remain high. Adjuvant therapy has demonstrated mixed results in clinical trials; thus the optimal adjuvant treatment of resected pancreatic cancer remains unclear. The purpose of this article is to review and assess the pertinent literature and try to determine an acceptable and uniform approach to adjuvant therapy in patients with resected adenocarcinoma of the pancreas. We focus on adjuvant chemotherapy and chemoradiation, and their impact on overall survival in this subgroup of patients.

Original languageEnglish (US)
JournalEuropean journal of Clinical and Medical Oncology
Volume2
Issue number1
StatePublished - 2010

Fingerprint

Adjuvant Radiotherapy
Adjuvant Chemotherapy
Adenocarcinoma
Survival
Pancreatic Neoplasms
Pancreas
Neoplasms
Therapeutics
Clinical Trials
Recurrence

Keywords

  • Adenocarcinoma
  • Adjuvant
  • Chemoradiation
  • Chemotherapy
  • Pancreas
  • Radiotherapy
  • Surgery

ASJC Scopus subject areas

  • Oncology

Cite this

Neben-Wittich, M. A., Stauder, M. C., Quevedo, F., Corsini, M. M., Iott, M. J., & Miller, R. C. (2010). Adjuvant radiotherapy and chemotherapy for resected pancreatic adenocarcinoma: Review of current evidence. European journal of Clinical and Medical Oncology, 2(1).

Adjuvant radiotherapy and chemotherapy for resected pancreatic adenocarcinoma : Review of current evidence. / Neben-Wittich, Michelle A.; Stauder, Michael C.; Quevedo, Fernando; Corsini, Michele M.; Iott, Matthew J.; Miller, Robert C.

In: European journal of Clinical and Medical Oncology, Vol. 2, No. 1, 2010.

Research output: Contribution to journalArticle

Neben-Wittich, MA, Stauder, MC, Quevedo, F, Corsini, MM, Iott, MJ & Miller, RC 2010, 'Adjuvant radiotherapy and chemotherapy for resected pancreatic adenocarcinoma: Review of current evidence', European journal of Clinical and Medical Oncology, vol. 2, no. 1.
Neben-Wittich, Michelle A. ; Stauder, Michael C. ; Quevedo, Fernando ; Corsini, Michele M. ; Iott, Matthew J. ; Miller, Robert C. / Adjuvant radiotherapy and chemotherapy for resected pancreatic adenocarcinoma : Review of current evidence. In: European journal of Clinical and Medical Oncology. 2010 ; Vol. 2, No. 1.
@article{43ce501eee964ca4865598c99f346834,
title = "Adjuvant radiotherapy and chemotherapy for resected pancreatic adenocarcinoma: Review of current evidence",
abstract = "Pancreatic adenocarcinoma is an aggressive cancer with an overall 5-year survival of 5{\%} or less. In patients who have resectable tumors, resection can lead to an improvement in overall survival, but local and distant recurrence rates remain high. Adjuvant therapy has demonstrated mixed results in clinical trials; thus the optimal adjuvant treatment of resected pancreatic cancer remains unclear. The purpose of this article is to review and assess the pertinent literature and try to determine an acceptable and uniform approach to adjuvant therapy in patients with resected adenocarcinoma of the pancreas. We focus on adjuvant chemotherapy and chemoradiation, and their impact on overall survival in this subgroup of patients.",
keywords = "Adenocarcinoma, Adjuvant, Chemoradiation, Chemotherapy, Pancreas, Radiotherapy, Surgery",
author = "Neben-Wittich, {Michelle A.} and Stauder, {Michael C.} and Fernando Quevedo and Corsini, {Michele M.} and Iott, {Matthew J.} and Miller, {Robert C.}",
year = "2010",
language = "English (US)",
volume = "2",
journal = "European journal of Clinical and Medical Oncology",
issn = "1759-8958",
publisher = "San Lucas Medical",
number = "1",

}

TY - JOUR

T1 - Adjuvant radiotherapy and chemotherapy for resected pancreatic adenocarcinoma

T2 - Review of current evidence

AU - Neben-Wittich, Michelle A.

AU - Stauder, Michael C.

AU - Quevedo, Fernando

AU - Corsini, Michele M.

AU - Iott, Matthew J.

AU - Miller, Robert C.

PY - 2010

Y1 - 2010

N2 - Pancreatic adenocarcinoma is an aggressive cancer with an overall 5-year survival of 5% or less. In patients who have resectable tumors, resection can lead to an improvement in overall survival, but local and distant recurrence rates remain high. Adjuvant therapy has demonstrated mixed results in clinical trials; thus the optimal adjuvant treatment of resected pancreatic cancer remains unclear. The purpose of this article is to review and assess the pertinent literature and try to determine an acceptable and uniform approach to adjuvant therapy in patients with resected adenocarcinoma of the pancreas. We focus on adjuvant chemotherapy and chemoradiation, and their impact on overall survival in this subgroup of patients.

AB - Pancreatic adenocarcinoma is an aggressive cancer with an overall 5-year survival of 5% or less. In patients who have resectable tumors, resection can lead to an improvement in overall survival, but local and distant recurrence rates remain high. Adjuvant therapy has demonstrated mixed results in clinical trials; thus the optimal adjuvant treatment of resected pancreatic cancer remains unclear. The purpose of this article is to review and assess the pertinent literature and try to determine an acceptable and uniform approach to adjuvant therapy in patients with resected adenocarcinoma of the pancreas. We focus on adjuvant chemotherapy and chemoradiation, and their impact on overall survival in this subgroup of patients.

KW - Adenocarcinoma

KW - Adjuvant

KW - Chemoradiation

KW - Chemotherapy

KW - Pancreas

KW - Radiotherapy

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=77956270887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956270887&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77956270887

VL - 2

JO - European journal of Clinical and Medical Oncology

JF - European journal of Clinical and Medical Oncology

SN - 1759-8958

IS - 1

ER -